Yahoo
NYSE - Nasdaq Real Time Price USD

STERIS plc (STE)

228.60 -3.54 (-1.52%)
As of 12:15:02 PM EDT. Market Open.
Trade STERIS on Coinbase
Dividend
STE announced a cash dividend of $0.69 with an ex-date of Nov. 17, 2026
Chart Range Bar
Loading chart for STE

What's happening with STE?

28m ago
Powered by Yahoo Scout

STERIS is approaching its fiscal second-quarter report with consensus calling for $1.56 billion in revenueand $2.67 adjusted EPS, while investors assess the impact of the Xodus Medical acquisition. The company also declared a $0.69 quarterly dividend, and recent coverage highlights stronger Healthcare growth alongside softer Applied Sterilization Technologies demand.

Powered by Yahoo Scout
  • Previous Close 232.14
  • Open 233.98
  • Bid 228.58 x 10000
  • Ask 229.31 x 10000
  • Day's Range 227.88 - 233.35
  • 52 Week Range 195.14 - 269.44
  • Volume 240,907
  • Avg. Volume 682,318
  • Market Cap (intraday) 22.289B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) 27.95
  • EPS (TTM) 8.18
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 2.76 (1.19%)
  • 1y Target Est 260.71
  • Morningstar Rating Rating available with Stock Picks access

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

www.steris.com

17,937

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

STE
9.05%
S&P 500 (^GSPC)
10.92%

1-Year Return

STE
2.38%
S&P 500 (^GSPC)
11.30%

3-Year Return

STE
12.46%
S&P 500 (^GSPC)
82.23%

5-Year Return

STE
2.43%
S&P 500 (^GSPC)
64.87%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 1.49B
Earnings 200.1M
Profit Margin 13.41%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
500M
1B
2B
13.0%
13.2%
13.4%
13.6%
13.8%

Analyst Insights

View More

Analyst Price Targets

232.00
260.71 Average
228.60 Current
275.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 275 -> 270

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.33%

  • Return on Assets (ttm)

    6.80%

  • Return on Equity (ttm)

    11.39%

  • Revenue (ttm)

    6.04B

  • Net Income Avi to Common (ttm)

    805M

  • Diluted EPS (ttm)

    8.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    482.3M

  • Total Debt/Equity (mrq)

    28.31%

  • Levered Free Cash Flow (ttm)

    798.86M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: